Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28725507 | 0.89 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL7666579 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNA | |
| SCHEMBL31582617 | 0.83 | SIGMAR1 (0.34) | ALDH1A1LMNAPLA2G1BPLA2G2A | |
| SCHEMBL5948663 | 0.75 | PLA2G1B (0.36) | PLA2G1BPLA2G2A | |
| SCHEMBL14313748 | 0.75 | PLA2G1B (0.36) | PLA2G1BPLA2G2A | |
| SCHEMBL5048808 | 0.74 | LMNA (0.42) | ALDH1A1LMNAPLA2G1BPLA2G2ATSHR | |
| SCHEMBL135129 | 0.74 | LMNA (0.42) | ALDH1A1LMNAPLA2G1BPLA2G2ATSHR | |
| SCHEMBL23798286 | 0.74 | ALDH1A1 (0.33) | ALDH1A1LMNA | |
| SCHEMBL3106003 | 0.74 | TSHR (0.43) | PLA2G1BPLA2G2ATSHR | |
| SCHEMBL5049367 | 0.74 | LMNA (0.42) | ALDH1A1LMNAPLA2G1BPLA2G2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516207-B2 | Aqueous primer composition and ink set, and printed matter | SAKATA INX CORPORATION (JP) | 2026-01-06 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210348011-A1 | AQUEOUS PRIMER COMPOSITION AND INK SET, AND PRINTED MATTER | SAKATA INX CORPORATION (JP) | 2021-11-11 | — | — | US | disclosed |
| EP-3878915-A1 | AQUEOUS PRIMER COMPOSITION AND INK SET, AND PRINTED MATTER | Sakata INX Corporation (JP) | 2021-09-15 | — | — | EP | disclosed |
| CN-112930376-A | Combination of water-based primer composition and ink, and printed matter | 阪田油墨股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885LMNA 918/4885PLA2G1B 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.